Orion Oyj (OTCMKTS:ORINY) Shares Up 3.7% – Time to Buy?

Orion Oyj (OTCMKTS:ORINY) was up 3.7% during trading on Tuesday . The company traded as high as $22.76 and last traded at $22.76. Approximately 296 shares changed hands during mid-day trading, a decline of 38% from the average daily volume of 478 shares. The stock had previously closed at $21.95.

Orion Oyj Stock Performance

The stock’s fifty day moving average price is $23.10 and its 200 day moving average price is $24.14. The stock has a market capitalization of $6.42 billion, a P/E ratio of 18.06 and a beta of 0.23. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.39 and a quick ratio of 1.29.

Orion Oyj (OTCMKTS:ORINY) last issued its earnings results on Tuesday, October 29th. The company reported $0.63 EPS for the quarter. The business had revenue of $517.97 million for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 41.41%. Research analysts forecast that Orion Oyj will post 1.18 earnings per share for the current year.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.